Proprio Raises $43M Series B Funding to Fuel Commercialization

First Light Field-Enabled Surgical Technology Company Secures Additional Institutional Capital to Drive Adoption of its AI-Driven Platform Proprio, a Seattle-based surgical technology company, today announced that it has secured $43 million in Series B funding from new and existing investors. The capital fuels commercialization to address significant demand for Proprio’s AI-driven surgical navigation platform in the US and overseas. Proprio’s flagship surgical navigation platform, Paradigm™, achieved a significant milestone this year by obtaining 510(k) clearance from the U.S. Food and Drug Administration (FDA). Paradigm harnesses the power of light field technology and artificial intelligence to generate a real-time 3D visualization of surgery. Paradigm provides surgeons with Volumetric Intelligence™, which uniquely combines medical images with live data from Paradigm’s sensor suite. The Paradigm system delivers many advantages for surgeons and patients. It eliminates the need for intraoperative scans, reducing radiation exposure to the patient and surgical staff. This saves up to 30 minutes per procedure, increasing the availability of care to patients. By quickly registering imaging data to the anatomy within surgical workflows, Paradigm delivers a high degree of accuracy and enables surgeons to maintain focus on the patient. Proprio’s live, 3D, multi-modal data represents a significant upgrade over current static approaches to surgical navigation and the c...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Alf Grunwald Bird B. AG FDA Gabriel Jones Health IT Funding Health IT Fundings Health IT Investment PARADIGM Proprio Source Type: blogs